

Amendments to the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

1-60 (canceled)

61. (previously presented) An isolated antibody or fragment thereof comprising the amino acid sequence of SEQ ID NO:60 and the amino acid sequence of SEQ ID NO:62.

62. (currently amended) The antibody or the fragment thereof of claim 61 wherein the antibody or the fragment thereof is selected from the group consisting of a whole immunoglobulin molecule, an scFv, a Fab fragment, an Fab' fragment, an F(ab')₂, an Fv, and a disulfide linked Fv.

63. (currently amended) The antibody or the fragment thereof of claim 61 wherein the antibody or the fragment thereof is monoclonal.

64. (currently amended) The antibody or the fragment thereof of claim 61 wherein the antibody or the fragment thereof is chimeric or humanized.

65. (currently amended) The antibody or the fragment thereof of claim 61 which comprises a heavy chain immunoglobulin constant domain.

66. (currently amended) The antibody or the fragment thereof of claim 65 wherein said heavy chain immunoglobulin constant domain is selected from the group consisting of an IgM constant domain, an IgG1 constant domain, an IgG2 constant domain, an IgG3 constant domain, an IgG4 constant domain and an IgA constant domain.

67. (currently amended) The antibody or the fragment thereof of claim 66 wherein said heavy chain immunoglobulin constant domain is human.

68. (currently amended) The antibody or the fragment thereof of claim 67 wherein said heavy chain immunoglobulin constant domain is a human IgG4 constant domain.

69. (currently amended) The antibody or the fragment thereof of claim 61 which comprises a light chain immunoglobulin constant domain.

70. (currently amended) The antibody or the fragment thereof of claim 69 which comprises a light chain immunoglobulin constant domain selected from the group consisting of a kappa constant domain and a lambda constant domain.

71. (currently amended) The antibody or the fragment thereof of claim 70 wherein said light chain immunoglobulin constant domain is human.

72. (currently amended) The antibody or the fragment thereof of claim 61 which comprises a human IgG4 heavy chain immunoglobulin constant domain and a human kappa chain immunoglobulin constant domain.

73. (currently amended) The antibody or the fragment thereof of claim 61 wherein the antibody or the fragment thereof is coupled or conjugated to a detectable label.

74. (currently amended) The antibody or the fragment thereof of claim 73, wherein the detectable label is a radiolabel.

75. (currently amended) The antibody or the fragment thereof of claim 74, wherein the radiolabel is ^{125}I , ^{131}I , ^{111}In , ^{90}Y , ^{99}Tc , ^{177}Lu , ^{166}Ho , or ^{153}Sm .

76. (currently amended) The antibody or the fragment thereof of claim 73, wherein the detectable label is an enzyme, a fluorescent label, a luminescent label, or a bioluminescent label.

77. (currently amended) The antibody or the fragment thereof of claim 61 wherein the antibody or fragment thereof is biotinylated.

78. (currently amended) The antibody or the fragment thereof of claim 61 wherein the antibody or the fragment thereof is attached to a solid support.

79. (currently amended) An isolated cell or cell line that produces the antibody or the fragment thereof of claim 61.

80. (currently amended) The antibody or the fragment thereof of claim 61 wherein the antibody or the fragment thereof inhibits the binding of HIV virus to CCR5 expressing cells.

81. (currently amended) The antibody or the fragment thereof of claim 61 wherein the antibody or the fragment thereof inhibits the ability of HIV virus to infect CCR5 expressing cells.

82. (previously presented) The XF11.1D8 hybridoma cell line deposited under ATCC Deposit Accession Number PTA-3030.

83. (previously presented) The antibody produced by the XF11.1D8 hybridoma cell line of claim 82.

84. (withdrawn - currently amended) A method of detecting expression of a G-protein Chemokine Receptor (CCR5) polypeptide in a biological sample from an individual comprising:

(a) contacting the biological sample with the antibody or the fragment thereof of claim 61 ~~assaying the expression of a G-protein Chemokine Receptor (CCR5) polypeptide in a biological sample from an individual using the antibody of claim 61;~~
and

(b) detecting the presence of the antibody or the fragment thereof that is specifically bound to CCR5 polypeptide from the biological sample;
wherein detection of the presence of the antibody or the fragment thereof specifically bound to CCR5 polypeptide indicates expression of CCR5 polypeptide~~comparing the level of a G-protein Chemokine Receptor (CCR5) polypeptide with a standard level of a G-protein Chemokine Receptor (CCR5) polypeptide.~~